June 4, 2009 - Lantheus Medical Imaging Inc. said today the company’s leading imaging agent, Cardiolite (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), was used in a recently completed five-year study examining appropriate treatment regimens for patients with type 2 diabetes and coronary artery disease.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now